LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 67
Next
>>
>
251 to 275 of 1656 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Vorinostat	180614_BG_03	17415	0.0189	54	277	9	3	Vorinostat	0.003326667	treatment	72	1	MCF10A-GM_6	331	0.0187	889.0	105.5	17054	348.0	0.0200	-0.00134	1.0098
Vorinostat	180614_BG_02	16445	0.0225	47	324	6	11	Vorinostat	0.003326667	treatment	72	1	MCF10A-GM_2	371	0.0221	889.0	105.5	17054	348.0	0.0200	0.00207	0.9830
Vorinostat	180614_BG_04	16418	0.0235	129	260	12	18	Vorinostat	0.003326667	treatment	72	1	MCF10A-GM_9	389	0.0231	889.0	105.5	17054	348.0	0.0200	0.00315	0.9822
Palbociclib	180614_BG_02	16577	0.0169	35	245	12	17	Palbociclib	0.003326667	treatment	72	1	MCF10A-GM_1	280	0.0166	889.0	105.5	17054	348.0	0.0200	-0.00339	0.9867
Trametinib	180622_BG_6	7466	0.0381	155	135	13	18	Trametinib	0.003326667	treatment	72	2	MCF10A-GM_3	290	0.0374	832.0	168.3	20016	537.9	0.0261	0.01127	0.6132
Palbociclib	180614_BG_03	16771	0.0236	93	305	13	7	Palbociclib	0.003326667	treatment	72	1	MCF10A-GM_6	398	0.0232	889.0	105.5	17054	348.0	0.0200	0.00319	0.9922
Neratinib	180622_BG_6	18955	0.0266	139	369	13	12	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_3	508	0.0261	832.0	168.3	20016	537.9	0.0261	-0.00002	0.9764
Alpelisib	180622_BG_6	20368	0.0292	92	505	12	14	Alpelisib	0.003326667	treatment	72	2	MCF10A-GM_3	597	0.0285	832.0	168.3	20016	537.9	0.0261	0.00235	1.0076
Alpelisib	180614_BG_03	17461	0.0174	55	249	13	15	Alpelisib	0.003326667	treatment	72	1	MCF10A-GM_6	304	0.0171	889.0	105.5	17054	348.0	0.0200	-0.00288	1.0111
Neratinib	180622_BG_8	19948	0.0250	33	466	6	7	Neratinib	0.003326667	treatment	72	2	MCF10A-GM_9	499	0.0244	832.0	168.3	20016	537.9	0.0261	-0.00172	0.9985
Trametinib	180622_BG_7	7553	0.0334	107	149	7	3	Trametinib	0.003326667	treatment	72	2	MCF10A-GM_4	256	0.0328	832.0	168.3	20016	537.9	0.0261	0.00666	0.6173
Trametinib	180622_BG_7	7891	0.0230	50	133	13	21	Trametinib	0.003326667	treatment	72	2	MCF10A-GM_6	183	0.0227	832.0	168.3	20016	537.9	0.0261	-0.00346	0.6328
Alpelisib	180703_BG_10	21342	0.0259	35	518	12	14	Alpelisib	0.003326667	treatment	72	3	MCF10A-GM_3	553	0.0253	1387.8	74.9	21564	711.9	0.0318	-0.00654	0.9948
Etoposide	180622_BG_7	19471	0.0193	45	332	12	18	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_6	377	0.0190	832.0	168.3	20016	537.9	0.0261	-0.00713	0.9880
Dasatinib	180622_BG_7	19473	0.0158	32	276	10	18	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_5	308	0.0156	832.0	168.3	20016	537.9	0.0261	-0.01055	0.9880
Etoposide	180622_BG_8	21315	0.0229	52	438	11	4	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_7	490	0.0225	832.0	168.3	20016	537.9	0.0261	-0.00365	1.0276
Etoposide	180622_BG_7	20449	0.0260	53	481	10	3	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_4	534	0.0254	832.0	168.3	20016	537.9	0.0261	-0.00068	1.0093
Dasatinib	180622_BG_7	19050	0.0223	41	385	13	18	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_6	426	0.0219	832.0	168.3	20016	537.9	0.0261	-0.00425	0.9785
Etoposide	180622_BG_7	19564	0.0203	35	362	10	20	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_5	397	0.0199	832.0	168.3	20016	537.9	0.0261	-0.00624	0.9901
Etoposide	180622_BG_8	19762	0.0243	31	450	11	7	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_8	481	0.0238	832.0	168.3	20016	537.9	0.0261	-0.00236	0.9944
Dasatinib	180622_BG_8	20978	0.0317	59	608	11	19	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_9	667	0.0308	832.0	168.3	20016	537.9	0.0261	0.00469	1.0206
Dasatinib	180622_BG_6	18449	0.0243	99	351	12	4	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_3	450	0.0238	832.0	168.3	20016	537.9	0.0261	-0.00231	0.9648
Dasatinib	180622_BG_7	19501	0.0232	68	386	10	17	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_4	454	0.0228	832.0	168.3	20016	537.9	0.0261	-0.00337	0.9887
Dasatinib	180622_BG_8	17506	0.0248	53	383	6	19	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_7	436	0.0243	832.0	168.3	20016	537.9	0.0261	-0.00182	0.9424
Etoposide	180622_BG_8	19941	0.0272	49	495	14	8	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_9	544	0.0266	832.0	168.3	20016	537.9	0.0261	0.00043	0.9984

|<
<<
Previous
Page 11 of 67
Next
>>
>
251 to 275 of 1656 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)